DGAP-News: Novavax Announces Management Promotions to

DGAP-News: Novavax, Inc. / Novavax Announces Management Promotions to Support Expanded Clinical Activity in 2014 13.01.2014 / 14:00 --------------------------------------------------------------------- ROCKVILLE, Md., 2014-01-13 14:00 CET (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced a number of promotions within its clinical operations group in preparation for expanded clinical trial activities in 2014 and 2015. Gregory M. Glenn, M.D. has been named Senior Vice President, Research and Development. Dr. Glenn joined Novavax in July 2010 as Senior Vice President, Chief Scientific Officer and in January 2011, was named Senior Vice President, Chief Medical Officer. Dr. Glenn has 22 years in translational vaccine development, including discovery, preclinical and clinical development in viral, bacterial and parasitic vaccines and has authored over 65 peer-reviewed publications. Prior to joining the Company, Dr. Glenn was the Chief Scientific Officer and founder of Iomai Corporation, which was acquired by Intercell in 2008. He began his vaccine research career at the Walter Reed Army Institute of Research, was board-certified in pediatrics and received his medical degree from Oral Roberts University School of Medicine. Louis F. Fries III, M.D. has been named Vice President, Chief Medical Officer. Dr. Fries was Vice President of Clinical and Medical Affairs when he joined Novavax in April of 2011. He had formerly served as Director of Clinical Development for GSK biologicals following the acquisition of ID Biomedical by GSK in 2005, and previously had been Vice President of Clinical and Regulatory Affairs at ID Biomedical. Dr. Fries received his medical degree from Duke University, has nearly 25 years of experience in the clinical testing and development of human vaccines, and has authored over 60 peer-reviewed publications. The Company also announced the appointment of D. Nigel Thomas, Ph.D. to Vice President, Clinical Operations. Dr. Thomas also joined the company in April of 2011 as Executive Director, Clinical Operations. Most recently, Dr. Thomas had been Clinical Operations Director at Iomai beginning in 2006 and through its acquisition by Intercell. He has previously held a variety of clinical operation positions in the Biotechnology and CRO industry. Dr. Thomas received his Ph.D. in Biochemistry & Physiology from the University of Reading in the United Kingdom and has overseen numerous vaccine, drug and medical device clinical trials including global Phase 2 and Phase 3 clinical trials for vaccines. 'I am very pleased to announce these promotions within the Novavax management team. Over the last couple years, Novavax has consistently demonstrated the ability to deliver on our clinical trials, thanks in large part to the work of Greg, Lou and Nigel. Novavax' ability to bring important, and in the case of our RSV and our H7N9 influenza trials, industry-changing, clinical results has positioned us for a critical couple of years of expanded clinical trial activity,' said Stanley C. Erck, President and CEO. About Novavax Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Additional information about Novavax is available on the company's website, novavax.com. CONTACT: Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 News Source: NASDAQ OMX End of Corporate News --------------------------------------------------------------------- 13.01.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Novavax, Inc. United States ISIN: US6700021040 End of News DGAP News-Service --------------------------------------------------------------------- 247765 13.01.2014